Letters Pain and agitation in dementia

Authors’ reply to McShane and Regnard

BMJ 2011; 343 doi: https://doi.org/10.1136/bmj.d5356 (Published 23 August 2011) Cite this as: BMJ 2011;343:d5356
  1. Dag Aarsland, professor1,
  2. Bettina Husebo, postdoctoral fellow2,
  3. Clive Ballard, professor3
  1. 1Department of Psychiatry, Stavanger University Hospital, 4011 Stavanger, Norway,
  2. 2Department of Public Health and Primary Health Care, University of Bergen, 5020 Bergen, Norway
  3. 3Wolfson Centre for Age-Related Diseases, Wolfson Wing and Hodgkin Building, Guy’s Campus, King’s College, London SE1 1UL, UK
  1. clive.ballard{at}kcl.ac.uk

The absence of a placebo group is an obvious and acknowledged consideration in the interpretation of our results.1 Our point is that the effect size compared with the control condition of treatment as usual was within the magnitude reported by others with antipsychotic drugs,2 …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe